Compare AMX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMX | TAK |
|---|---|---|
| Founded | 2000 | 1781 |
| Country | Mexico | Japan |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.7B | 57.6B |
| IPO Year | 2000 | 2007 |
| Metric | AMX | TAK |
|---|---|---|
| Price | $20.78 | $17.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 3 |
| Target Price | ★ $29.44 | $22.07 |
| AVG Volume (30 Days) | ★ 2.2M | 2.0M |
| Earning Date | 10-13-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.80% | 2.71% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.77 | $4.39 |
| Revenue Next Year | $4.97 | $1.93 |
| P/E Ratio | ★ $15.78 | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.71 | $12.99 |
| 52 Week High | $28.46 | $19.10 |
| Indicator | AMX | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 19.54 | 43.49 |
| Support Level | $20.37 | $17.95 |
| Resistance Level | $24.05 | $18.91 |
| Average True Range (ATR) | 0.43 | 0.19 |
| MACD | -0.10 | -0.11 |
| Stochastic Oscillator | 1.34 | 1.46 |
América Móvil is the largest telecom carrier in Latin America, serving about 335 million wireless customers across the region. It also provides fixed-line phone, internet access, and television services in most of the countries it serves. Mexico is the firm's largest market, providing about 35% of service revenue. Móvil dominates the Mexican wireless market with about 60% customer share and also serves about half of the country's fixed-line internet access customers. Brazil, its second-most important market, accounts for about 20% of service revenue. Móvil sold its low-margin wireless resale business in the US to Verizon in 2021 and now owns a 1.4% stake in the US telecom giant. The firm also holds a 61% stake in Telekom Austria.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.